Clinical Policy: Genetic Testing Eye Disorders

Reference Number: CP.MP.220
Date of Last Revision: 02/22

Coding Implications
Revision Log

See Important Reminder at the end of this policy for important regulatory and legal information.

Description
In the past 15 years, genetics experts have identified approximately 500 genes that contribute to inherited eye diseases. Approximately 4,000 diseases affect humans, and nearly one-third of these diseases may affect the eyes. Because many genes involved in ophthalmologic disorders are now identified, scientists have developed a better understanding of how these genes influence vision and eye health.

Age-related macular degeneration (AMD) is an eye condition that causes damage to the central portion of the retina (the macula), affecting the ability to see objects straight ahead. It is a complex disease and is the leading cause of blindness and irreversible vision loss among adults over the age of 65 years. The etiology of AMD is multifactorial and includes both genetic and environmental (eg, age, smoking) factors. Genetic testing has been proposed to predict the risk of developing advanced AMD in asymptomatic individuals, however, the clinical utility of genetic testing for age-related macular degeneration is limited. No studies have shown improvements in patients identified as being high-risk based on genetic testing, and evidence is insufficient to determine the effects of genetic testing on health outcomes. For individuals who have age-related macular degeneration, the clinical utility of genetic testing is limited and has not shown to be superior to clinical evaluation.

The molecular genetic basis for glaucoma has not been clearly elucidated, however a small subset of genes have been identified in very rare forms of congenital glaucoma.

Inherited retinal dystrophy can be caused by biallelic variants in the RPE65 gene and other genes and can result in difficulty seeing in dim light and progressive loss of vision. Historically considered untreatable, gene therapy has been proposed as a treatment to improve visual function. Individuals who have vision loss due to biallelic RPE65 variant associated retinal dystrophy are eligible to receive gene therapy. Because this is a rare condition, there are challenges with generating evidence demonstrating that the technology results in a meaningful improvement in net health outcomes.

Below is a list of higher volume tests and the associated laboratories for each criteria section. This list is not all inclusive.

<table>
<thead>
<tr>
<th>CPT® Codes</th>
<th>Example Tests (Labs)</th>
<th>Criteria Section</th>
<th>Common ICD Codes</th>
</tr>
</thead>
<tbody>
<tr>
<td>81403</td>
<td>Targeted Mutation Analysis for a Known Familial Variant</td>
<td>Known Familial Variant Analysis</td>
<td>N/A</td>
</tr>
<tr>
<td>81401, 81479, 81599</td>
<td>Macula Risk® (ArcticDX, Inc.)</td>
<td>Macular Degeneration</td>
<td>H35.30, H35.3110-H35.3194, H35.3210-H35.3293, Z13.5</td>
</tr>
<tr>
<td>CPT® Codes</td>
<td>Example Tests (Labs)</td>
<td>Criteria Section</td>
<td>Common ICD Codes</td>
</tr>
<tr>
<td>--------------</td>
<td>------------------------------------------------------------------------------------</td>
<td>--------------------------------</td>
<td>-------------------------------------------------------</td>
</tr>
<tr>
<td>0205U</td>
<td>Vita Risk® (ArcticDX, Inc.)</td>
<td>Macular Degeneration</td>
<td>H35.30, H35.3110-H35.3194, H35.3210-H35.3293, Z13.5</td>
</tr>
<tr>
<td>81405, 81408, 81479</td>
<td>Macular Degeneration NGS Panel (Sequencing &amp; Deletion/Duplication) (Fulgent Genetics)</td>
<td>Macular Degeneration</td>
<td>H35.30, H35.3110-H35.3194, H35.3210-H35.3293, Z13.5</td>
</tr>
<tr>
<td>81406</td>
<td>RPE65 Sequencing Analysis RPE65 Deletion/Duplication Analysis</td>
<td>RPE65 Sequencing and/or Deletion/Duplication Analysis or Multigene Panel Analysis</td>
<td>H35.50-H35.54</td>
</tr>
<tr>
<td>81479</td>
<td>Invitae Glaucoma Panel (Invitae)</td>
<td>Glaucoma</td>
<td>H40</td>
</tr>
<tr>
<td></td>
<td>Glaucoma Panel (GeneDx)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Glaucoma Panel (PreventionGenetics)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>81400-81408</td>
<td>See Below</td>
<td>Other Eye Disorders</td>
<td>N/A</td>
</tr>
</tbody>
</table>

This policy document provides criteria for Genetic Testing for Eye Disorders. Please refer to:

- **CP.MP.220 Genetic Testing: Hereditary Cancer Susceptibility** for criteria related to genetic testing for retinoblastoma.

- **CP.MP.223 Genetic Testing: Hearing Loss** for criteria related to genetic testing for disorders that include hearing loss, such as Usher syndrome.

- **CP.MP.230 Genetic Testing: Multisystem Inherited Disorders, Intellectual Disability, and Developmental Delay** for criteria related to oculocutaneous albinism and other multisystem inherited disorders.

- **CP.MP.222 Genetic Testing: General Approach to Genetic Testing** for criteria related to genetic testing for eye disorders that are not specifically discussed in this or another non-general policy.

**Policy/Criteria**

Known Familial Variant Analysis for Eye Disorders
I. It is the policy of health plans affiliated with Centene Corporation® that Targeted mutation analysis for a known familial variant (81403) for an eye disorder is considered medically necessary when:
   A. The member/enrollee has a close relative with a known pathogenic or likely pathogenic variant causing the condition.

II. It is the policy of health plans affiliated with Centene Corporation® that current evidence does not support targeted mutation analysis for a known familial variant (81403) for an eye disorder for all other indications.

Macular Degeneration
   I. It is the policy of health plans affiliated with Centene Corporation® that current evidence does not support genetic testing for macular degeneration (81401, 81405, 81406, 81408, 81479, 81599, 0205U).

RPE65-Associated Retinal Dystrophy/Leber Congenital Amaurosis
   RPE65 Sequencing and/or Deletion/Duplication Analysis or Multigene Panel Analysis
      I. It is the policy of health plans affiliated with Centene Corporation® that genetic testing for RPE65-associated retinal dystrophy / Leber congenital amaurosis via RPE65 sequencing and/or deletion/duplication analysis (81406) or a multigene panel (81434) that includes RPE65 is considered medically necessary when meeting both of the following:
         A. The member/enrollee has a diagnosis of a retinal dystrophy or Leber Congenital Amaurosis,
         B. The member/enrollee is being considered for treatment with voretigene neparvovec (Luxturna®).
      II. It is the policy of health plans affiliated with Centene Corporation® that current evidence does not support genetic testing for RPE65-associated retinal dystrophy / Leber congenital amaurosis via RPE65 sequencing and/or deletion/duplication analysis (81406) or a multigene panel (81434) that includes RPE65 for all other indications.

Glaucoma
   I. It is the policy of health plans affiliated with Centene Corporation® that current evidence does not support genetic testing for glaucoma (81479).

Other Eye Disorders

The following is a list of conditions that have a known genetic association. Due to their relative rareness, these genetic tests may be appropriate to establish or confirm a diagnosis.
   I. It is the policy of health plans affiliated with Centene Corporation® that genetic testing to establish or confirm one of the following eye disorders to guide management is considered medically necessary when the member/enrollee demonstrates clinical
Clinical Policy
Genetic Testing Eye Disorders

features* consistent with the disorder (the list is not meant to be comprehensive, see II below):

A. Duane Syndrome
B. Familial Exudative Vitreoretinopathy
C. Retinitis Pigmentosa
D. Aniridia
E. X-linked Congenital Retinoschisis
F. Presenile Cataracts

II. It is the policy of health plans affiliated with Centene Corporation® that genetic testing to establish or confirm the diagnosis of all other eye disorders not specifically discussed within this or another medical policy will be evaluated by the criteria outlined in General Approach to Genetic Testing (see policy for criteria).

Clinical features for a specific disorder may be outlined in resources such as GeneReviews, OMIM, National Library of Medicine, Genetics Home Reference, or other scholarly source.

Notes and Definitions
Age-related Macular Degeneration (AMD) is the leading cause of blindness and irreversible vision loss among older adults (>65 years).

Retinal dystrophies (RDs) are degenerative diseases of the retina which have marked clinical and genetic heterogeneity. Vision impairment may vary from poor peripheral or night vision to complete blindness, and severity usually increases with age.

RPE65 (retinal pigment epithelium-specific protein 65-kD) gene encodes the RPE54 protein is an all translate-retinal isomerase, a key enzyme expressed in the retinal pigment epithelium (RPE) that is responsible for regeneration of 11-cis-retinol in the visual cycle.

Gene Therapies are treatments that change the expression of genes to treat disease, eg, by replacing or inactivating a gene that is not functioning properly or by introducing a new gene. Genes may be introduced into human cells through a vector, usually a virus.

Close relatives include first, second, and third degree relatives on the same side of the family:
1. First-degree relatives are parents, siblings, and children
2. Second-degree relatives are grandparents, aunts, uncles, nieces, nephews, grandchildren, and half siblings
3. Third-degree relatives are great grandparents, great aunts, great uncles, great grandchildren, and first cousins.

The purpose of genetic testing of asymptomatic individuals with risk of developing age-related macular degeneration is to identify single nucleotide variants for primary prevention or earlier detection of disease for more timely intervention to affect course of disease progression. Patients may be referred from primary care to an ophthalmologist or medical geneticist for investigation.
Clinical Policy
Genetic Testing Eye Disorders

and management of age-related macular degeneration. In all cases, the patient should receive counseling from a physician with expertise in inherited disease of a genetic counselor.

Whenever clinical findings suggest the presence of an inherited eye disease, the treating ophthalmologist should either discuss the potential value of genetic testing with their patient and order the appropriate tests (if any) or should offer a referral to another physician or counselor with expertise in the selection and interpretation of genetic tests. Treating physicians should also ensure that their patients receive a written copy of their genetic test results.

Genetic testing is required to detect the presence of pathogenic or likely pathogenic variants in the RPE65 gene in individuals with documented vision loss. By definition, pathogenic or likely pathogenic variant(s) must be present in both copies of the RPE65 gene to establish a diagnosis of biallelic RPE65-mediated inherited retinal dystrophy. Next-generation sequencing and Sanger sequencing typically cannot resolve the phase (eg, trans vs. cis configuration) when two RPE65 pathogenic or likely pathogenic variants are detected. In this scenario, additional documentation of the trans configuration is required to establish a diagnosis of biallelic RPE65-mediated inherited retinal dystrophy.

In all cases, the patient should receive counseling from a physician with expertise in inherited disease of a genetic counselor. Whenever clinical findings suggest the presence of an inherited eye disease, the treating ophthalmologist should either discuss the potential value of genetic testing with their patient and order the appropriate tests (if any) or should offer a referral to another physician or counselor with expertise in the selection and interpretation of genetic tests. Treating physicians should also ensure that their patients receive a written copy of their genetic test results.

Background

American Academy of Ophthalmology (AAO)
The American Academy of Ophthalmology (AAO) Task Force on Genetic Testing published the following recommendations for genetic testing of inherited eye diseases (2014):

1. Offer genetic testing to patients with clinical findings suggestive of a Mendelian disorder whose causative gene(s) have been identified. If unfamiliar with such testing, refer the patient to a physician or counselor who is. In all cases, ensure that the patient receives counseling from a physician with expertise in inherited disease or a certified genetic counselor.

2. Use Clinical Laboratories Improvement Amendments– approved laboratories for all clinical testing. When possible, use laboratories that include in their reports estimates of the pathogenicity of observed genetic variants that are based on a review of the medical literature and databases of disease-causing and non–disease-causing variants.

3. Provide a copy of each genetic test report to the patient so that she or he will be able independently to seek mechanism-specific information, such as the availability of gene-specific clinical trials, should the patient wish to do so.

4. Avoid direct-to-consumer genetic testing and discourage patients from obtaining such tests themselves. Encourage the involvement of a trained physician, genetic counselor, or
Genetic Testing Eye Disorders

both for all genetic tests so that appropriate interpretation and counseling can be provided.

5. Avoid unnecessary parallel testing—order the most specific test(s) available given the patient’s clinical findings. Restrict massively parallel strategies like whole-exome sequencing and whole-genome sequencing to research studies conducted at tertiary care facilities.

6. Avoid routine genetic testing for genetically complex disorders like age-related macular degeneration and late-onset primary open-angle glaucoma until specific treatment or surveillance strategies have been shown in 1 or more published prospective clinical trials to be of benefit to individuals with specific disease-associated genotypes. In the meantime, confine the genotyping of such patients to research studies.

7. Avoid testing asymptomatic minors for untreatable disorders except in extraordinary circumstances. For the few cases in which such testing is believed to be warranted, the following steps should be taken before the test is performed: (1) the parents and child should undergo formal genetic counseling, (2) the certified counselor or physician performing the counseling should state his or her opinion in writing that the test is in the family’s best interest, and (3) all parents with custodial responsibility for the child should agree in writing with the decision to perform the test.

American Society of Retina Specialists (ASRS)
American Society of Retina Specialists published special correspondence on the use of genetic testing in the management of patients with age-related macular degeneration (2017), which made the following conclusions:

1. Age-related macular degeneration genetic testing may provide information on the progression rates from intermediate to advanced AMD. However, before ordering this testing, retina specialists should be aware of the following:
   a. Testing should be performed only at Clinical Laboratory Improvement Amendments–certified laboratories with expertise in genetic sequencing. Because of the high variability in the results, direct-to-consumer (DTC) AMD genetic testing that does not meet this standard is not recommended.
   b. Interpretation of the results of AMD genetic testing is complex.
   c. At present, there is no clinical evidence that altering the management of genetically higher risk progression patients, for example, with more frequent office visits and/or improved lifestyle changes, results in better visual outcomes for these patients compared with individuals of lower genetic susceptibility. As such, prospective studies are needed before patient care is modified.

2. Age-related macular degeneration genetic testing at present in patients with neovascular AMD does not provide clinically relevant information regarding response to anti-vascular endothelial growth factor (VEGF) treatment and is not recommended for this purpose.

3. Although genetic testing to determine the optimal nutritional supplementation may in the future prove useful, at present there is insufficient data to support the use of genetic testing in patients with AMD prior to recommendation of current Age-Related Eye Disease Study (AREDS) nutritional supplement use.

U.S. Food and Drug Administration (FDA)
The FDA issued an approval letter on December 18, 2017 for Luxturna stating, “Under this license, you are authorized to manufacture the product voretigene neparvovec-rzyl, which is
Genetic Testing Eye Disorders

indicated for the treatment of patients with confirmed biallelic RPE65 mutation-associated retinal dystrophy.”

National Institute for Health and Care Excellence
The National Institute for Health and Care Excellence published guidance for the use of voretigene neparvovec for treating inherited retinal dystrophies caused by RPE65 gene mutations, which stated the following:

1.1 Voretigene neparvovec is recommended, within its marketing authorisation, as an option for treating RPE65-mediated inherited retinal dystrophies in people with vision loss caused by inherited retinal dystrophy from confirmed biallelic RPE65 mutations and who have sufficient viable retinal cells. It is recommended only if the company provides voretigene neparvovec according to the commercial arrangement.

The committee noted that, “RPE65-mediated inherited retinal dystrophies are rare and serious. They involve progressive loss of vision. This ultimately leads to near-total blindness, and severely affects the quality of life of people with the condition, and their families and carers. Current treatment is supportive care. Clinical trial evidence shows that, in the short term, voretigene neparvovec improves vision and prevents the condition from getting worse. There is no long-term clinical evidence, but it is biologically plausible that the treatment effect is likely to continue for decades. Some assumptions in the economic modelling are uncertain, particularly around the utility values and how long the treatment effect lasts. Despite the uncertainties, voretigene neparvovec is likely to provide important clinical benefits for people with RPE65-mediated inherited retinal dystrophies, and is considered an appropriate use of NHS resources within the context of a highly specialised service. It is therefore recommended for use in the NHS.”

Coding Implications
This clinical policy references Current Procedural Terminology (CPT®). CPT® is a registered trademark of the American Medical Association. All CPT codes and descriptions are copyrighted 2021, American Medical Association. All rights reserved. CPT codes and CPT descriptions are from the current manuals and those included herein are not intended to be all-inclusive and are included for informational purposes only. Codes referenced in this clinical policy are for informational purposes only. Inclusion or exclusion of any codes does not guarantee coverage. Providers should reference the most up-to-date sources of professional coding guidance prior to the submission of claims for reimbursement of covered services.

<table>
<thead>
<tr>
<th>Reviews, Revisions, and Approvals</th>
<th>Revision Date</th>
<th>Approval Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Policy developed</td>
<td>02/22</td>
<td>02/22</td>
</tr>
</tbody>
</table>

References


Important Reminder
This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. The Health Plan makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved. “Health Plan” means a health plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or any of such health plan’s affiliates, as applicable.
The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable Health Plan-level administrative policies and procedures.

This clinical policy is effective as of the date determined by the Health Plan. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. The Health Plan retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of member/enrollees. This clinical policy is not intended to recommend treatment for member/enrollees. Member/enrollees should consult with their treating physician in connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom the Health Plan has no control or right of control. Providers are not agents or employees of the Health Plan.

This clinical policy is the property of the Health Plan. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, member/enrollee and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, member/enrollee and their representatives agree to be bound by such terms and conditions by providing services to member/enrollee and/or submitting claims for payment for such services.

**Note: For Medicaid member/enrollees**, when state Medicaid coverage provisions conflict with the coverage provisions in this clinical policy, state Medicaid coverage provisions take precedence. Please refer to the state Medicaid manual for any coverage provisions pertaining to this clinical policy.

**Note: For Medicare member/enrollees**, to ensure consistency with the Medicare National Coverage Determinations (NCD) and Local Coverage Determinations (LCD), all applicable NCDs, LCDs, and Medicare Coverage Articles should be reviewed prior to applying the criteria set forth in this clinical policy. Refer to the CMS website at [http://www.cms.gov](http://www.cms.gov) for additional information.

©2016 Centene Corporation. All rights reserved. All materials are exclusively owned by Centene Corporation and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Centene Corporation. You may not alter or remove any trademark, copyright or other notice contained herein. Centene® and Centene Corporation® are registered trademarks exclusively owned by Centene Corporation.